<DOC>
	<DOCNO>NCT00133042</DOCNO>
	<brief_summary>The purpose study determine whether addition omalizumab patient poorly control asthma ( poor adherence ) decrease allergic airway inflammation improve asthma control .</brief_summary>
	<brief_title>The Effect Omalizumab Airway Responsiveness Adenosine Patients With Poorly Controlled Asthma</brief_title>
	<detailed_description>Patients moderate severe allergic asthma poorly adherent inhaled corticosteroid ( ICS ) persistent airway inflammation result excessive morbidity sometimes death . Omalizumab ( OMB ) , anti-IgE monoclonal antibody decrease release mediator mast cell , reduces frequency exacerbation allow reduction ICS dose . However , data effect OMB airway inflammation . Bronchoprovocation adenosine 5 ' monophosphate ( AMP ) robust sensitive non-invasive measure allergic airway inflammation , effect OMB surrogate marker previously report . Based upon mechanisms action OMB AMP fact OMB administer 2-4 week interval clinic ( i.e. , direct observe therapy ) , hypothesis treatment new agent reduce airway responsiveness AMP compensate poor adherence ICS . To test hypothesis , select 16 patient ( 6-26 yr ) total IgE 30-1300 IU/ml , sensitivity least one allergen , FEV1 ≥ 60 % predict , documented poor adherence ICS inadequate asthma control . Subjects randomize receive OMB ( 150-375 mg subcutaneously ) placebo every 2-4 week four month , double-blind , crossover manner 3 month washout period treatment . Spirometry measure injection end treatment period . The concentration AMP provoke 20 % decrease FEV1 ( PC20 FEV1 ) free IgE serum concentration measure end treatment period . After randomization , 5-day course oral prednisone administer whenever bronchodilator-unresponsive symptom persist FEV1 &lt; 60 % predict . ANOVA repeat measure use evaluate difference treatment Δ PC20 ( primary endpoint ) Δ FEV1 , Friedman Statistic use evaluate difference number short course prednisone . The result study provide new information extent OMB decrease airway responsiveness AMP ( i.e . allergic airway inflammation ) whether new therapy fill unmet need patient inadequately control asthma poor adherence inhale corticosteroid .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Nonsmoking subject 626 year age Evidence poor asthma control Adherence ICS &lt; 50 % dos prescribe minimum 3 month Baseline FEV1 &gt; 60 % predict PC20 AMP &lt; 60 mg/ml Able perform American Thoracic Society ( ATS ) acceptable reproducible spirometry Cigarette smoking/use marijuana Pregnancy Respiratory infection past six week History acute allergic reaction asthma/allergy medication Total dose requirement omalizumab 375 mg every two week Inability withhold require medication challenge Abnormal electrocardiogram ( ECG )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>anti-IgE , omalizumab</keyword>
</DOC>